Vilon

Vilon is like a two-word instruction someone insists can rewrite an entire book: it does seem to nudge old cells in a test tube, but the claim that those two words rejuvenate a whole human being is a leap the actual experiments never made.

A synthetic dipeptide (Lys-Glu) proposed to act epigenetically: binding DNA/chromatin to drive deheterochromatinisation - loosening condensed chromatin back toward an active state - and thereby reactivating genes silenced in ageing cells, including in thymocytes and lymphocytes, with downstream effects on immune-cell proliferation and differentiation. These mechanisms are demonstrated mainly in vitro and in animals, not confirmed in living humans. Typically administered by injection in the grey market.

Research contexts. Not proven uses, and not recommendations.

Genuinely thin and easy to overstate. The only Vilon-specific human-derived data are in-vitro/ex-vivo cytogenetic studies in which peripheral blood lymphocytes taken from very elderly donors were exposed to Vilon in culture and showed reactivation of condensed chromatin and silenced genes (Lezhava and colleagues). These are cells in a dish, not treatment of living patients with measured clinical outcomes. There are no modern, adequately powered, independently run randomised controlled trials of Vilon in people, and no human study showing it prevents disease, improves immune function clinically, or extends lifespan. The frequently-cited '266 elderly patients over 6-8 years' longevity study used the peptide preparations Thymalin and Epithalamin - not Vilon - so attributing its mortality findings to Vilon is incorrect.

• !Human evidence is essentially in-vitro only; benefits in living people are unproven
• !Evidence base dominated by a single Russian research group with limited independent replication
• !Marketing routinely misattributes the Thymalin/Epithalamin longevity trial and other bioregulator data to Vilon
• !Sold in the UK as an unlicensed 'research chemical' / 'not for human consumption' - no MHRA oversight of identity, purity, sterility or dose
• !Grey-market injectable products carry contamination, mislabelling and sterility risks
• !Long-term human safety is essentially unknown; no proper clinical pharmacology or toxicology in people
• !An agent claimed to broadly reactivate silenced genes warrants caution given the role of dysregulated gene expression in cancer

Not a licensed medicine in the UK and not approved by the MHRA for any indication. It is not an authorised medicinal product, so any product sold or promoted with medicinal claims would fall foul of the Human Medicines Regulations 2012. In practice it is sold online as an unlicensed 'research chemical' labelled 'not for human consumption', outside any pharmaceutical quality, safety or efficacy control. Supplying it for human use, or marketing it with medical claims, is unlawful.

• · N/A· None found

  No registered modern interventional RCTs of Vilon in humans identified

  Searches did not surface contemporary registered clinical trials of Vilon (Lys-Glu) with clinical endpoints. Human-derived data are in-vitro cytogenetic studies, not trials.

1. 01
   A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice — Khavinson VKh, Anisimov VN, Doklady Biological Sciences (2000)

   Animal study (CBA mice): reduced spontaneous lung adenoma incidence and increased lifespan. A core preclinical claim for Vilon - note it is mice, not humans.

2. 02
   Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people — Lezhava T, Khavinson V, Monaselidze J, et al., Biogerontology (2004)

   The strongest Vilon-specific 'human' evidence - but in vitro: lymphocytes from elderly donors exposed in culture, showing deheterochromatinisation and gene reactivation. Not an in-vivo trial.

3. 03
   Anti-aging peptide bioregulators induce reactivation of chromatin — Lezhava T, Monaselidze J, Kadotani T, et al., Georgian Medical News (2006)

   In-vitro cytogenetic work comparing Epitalon, Livagen and Vilon in cells from old donors. Note: Vilon did NOT decondense pericentromeric structural heterochromatin (unlike the others) - the effect is selective, and this is a cell-level result, not a clinical outcome.

4. 04
   Epigenetic modification under the influence of peptide bioregulators on the 'old' chromatin — Lezhava T, Jokhadze T, Monaselidze J, et al., Georgian Medical News (2023)

   More recent epigenetic/chromatin study (lymphocytes from donors aged 75-88); still from the same lineage of investigators and not a clinical efficacy trial.

5. 05
   Peptides of pineal gland and thymus prolong human life (Thymalin/Epithalamin, 266 elderly subjects) — Khavinson VKh, Morozov VG, Neuroendocrinology Letters (2003)

   Cited here to correct a common error: this widely-quoted longevity study used Thymalin and Epithalamin, NOT Vilon. Methodologically weak by modern standards.

6. 06
   Vilon and Lys-Glu peptide - PubMed search — Various, PubMed (2026)

   Live search of the Vilon literature, predominantly rodent and in-vitro work from a small set of groups.